Monoclonal antibodies resources and updates
Monoclonal antibody treatment was given emergency use authorization by the U.S. Food and Drug Administration as a COVID-19 treatment in November 2020. The therapy, which is used in people who are at a higher risk of being hospitalized with COVID-19, boosts a person’s natural immune system so it’s stronger and better able to fight the coronavirus. It can be given to both vaccinated and unvaccinated people and stays in the body for around 90 days.
Evusheld resources and updates
Evusheld (tixagevimab/cilgavimab) is a long-acting monoclonal antibody that was recently issued
an emergency use authorization (EUA) by the Food and Drug Administration (FDA) for COVID-19
pre-exposure prophylaxis (PrEP) in certain high-risk, immunocompromised individuals. It is
administered through two intramuscular injections, repeated every six months. PrEP is not a
substitute for vaccination.
If you have questions regarding Evusheld, please contact Dr. Paul Chittick, section head, Infectious Diseases, Beaumont, Royal Oak.